Real-Life Effectiveness of Infliximab in the Treatment of Ankylosing Spondylitis: The Canadian Experience

被引：0
|
作者：
Rahinan, Proton [1 ]
Sampalis, John [2 ,3 ]
Khalil, Hayssam [4 ]
机构：
[1] Mem Univ Newfoundland, St John, NF, Canada
[2] McGill Univ, Westmount, PQ, Canada
[3] Univ Montreal, Westmount, PQ, Canada
[4] Schering Plough Canada inc, Montreal, PQ, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2010年 / 37卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5
引用
收藏
页码：1276 / 1276
页数：1
相关论文
共 50 条
  • [41] Are Patients with Ankylosing Spondylitis Willing to Pay for Treatment with Infliximab?
    Webers, Casper
    Essers, Ivette
    van Tubergen, Astrid
    Braun, Juergen
    Heldmann, Frank
    Baraliakos, Xenofon
    Boonen, Annelies
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [42] Acquired Erythrocytosis Upon Treatment with Infliximab for Ankylosing Spondylitis
    Antonelli, Maria
    Bupathi, Manojkumar
    Janakiram, Murali
    Hergenroeder, Paul
    Khan, Muhammad Asim
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (03) : 581 - 583
  • [43] Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis
    Vinagre, Filipe
    Santos, Maria Jose
    da Silva, J. Canas
    ACTA REUMATOLOGICA PORTUGUESA, 2007, 32 (03): : 271 - 276
  • [44] Infliximab treatment efficacy in lymphoedema associated with ankylosing spondylitis
    Almodóvar, R
    Zarco, P
    Quirós, FJ
    Mazzucchelli, R
    RHEUMATOLOGY, 2004, 43 (11) : 1456 - 1456
  • [45] Real Life Experience of First Course of Anti-TNF Treatment in Ankylosing Spondylitis Patients in Brazil
    de Machado M.A.Á.
    Almeida A.M.
    Kakehasi A.M.
    Acurcio F.A.
    Rheumatology and Therapy, 2016, 3 (1) : 143 - 154
  • [46] One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
    Chimenti, Maria Sole
    Fonti, Giulia Lavinia
    Conigliaro, Paola
    Sunzini, Flavia
    Scrivo, Rossana
    Navarini, Luca
    Triggianese, Paola
    Peluso, Giusy
    Scolieri, Palma
    Caccavale, Rosalba
    Diamanti, Andrea Picchianti
    De Martino, Erica
    Salemi, Simonetta
    Birra, Domenico
    Altobelli, Alessio
    Paroli, Marino
    Bruzzese, Vincenzo
    Lagana, Bruno
    Gremese, Elisa
    Conti, Fabrizio
    Afeltra, Antonella
    Perricone, Roberto
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (07) : 813 - 821
  • [47] ONE-YEAR EFFECTIVENESS, RETENTION RATE AND SAFETY OF SECUKINUMAB IN ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A REAL-LIFE MULTICENTRE STUDY
    Chimenti, M. S.
    Fonti, G. L.
    Conigliaro, P.
    Sunzini, F.
    Scrivo, R.
    Navarini, L.
    Triggianese, P.
    Peluso, G.
    Scolieri, P.
    Caccavale, R.
    Picchianti-Diamanti, A.
    De Martino, E.
    Salemi, S.
    Birra, D.
    Altobelli, A.
    Paroli, M.
    Bruzzese, V.
    Lagana, B.
    Gremese, E.
    Conti, F.
    Afeltra, A.
    Perricone, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 716 - 716
  • [48] ADALIMUMAB, ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS-COST EFFECTIVENESS ANALYSIS IN POLISH SETTINGS
    Macioch, T.
    Niewada, M.
    Wrona, W.
    Golicki, D.
    Hermanowski, T.
    VALUE IN HEALTH, 2008, 11 (06) : A543 - A543
  • [49] Ongoing clinical effectiveness and safety of treatment with Infliximab in patients with ankylosing Spondylitis over 6 years
    Baraliakos, X.
    Listing, J.
    Fritz, C.
    Alten, R.
    Burmester, G.
    Krause, A.
    Schewe, S.
    Schneider, S.
    Soerensen, H.
    Zeidler, H.
    Sieper, J.
    Braun, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 51 - 51
  • [50] Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
    Wailoo, Allan
    Bansback, Nick
    Chilcott, Jim
    RHEUMATOLOGY, 2008, 47 (02) : 119 - 120
12345